Vignesh Rajah - Jan 18, 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
SVP & CHIEF MEDICAL OFFICER
Signature
/s/ John LaRocca, Attorney-in-Fact
Stock symbol
YMAB
Transactions as of
Jan 18, 2024
Transactions value $
$0
Form type
4
Date filed
1/22/2024, 06:02 PM
Previous filing
Jan 30, 2023
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +17.8K +100% $0.00 35.6K Jan 18, 2024 Direct F1
holding YMAB Common Stock 4.27K Jan 18, 2024 By Spouse and minor F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +35.7K $0.00 35.7K Jan 18, 2024 Common Stock 35.7K $9.83 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 17,800 restricted stock units ("RSUs") granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU. The RSUs vest by 1/3 on each of January 18, 2025, January 18, 2026 and January 18, 2027 subject to the continuing employment of the Reporting Person on each vesting date.
F2 Includes 4,033 shares of common stock owned by Reporting Person's spouse and 233 held by Reporting Person's minor child. Reporting Person may be deemed to have a pecuniary interest in the securities due to family relationship.
F3 Reporting Person disclaims beneficial ownership of the securities reported and this report shall not be deemed an admission that Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act, as amended, or for any other purpose.
F4 Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F5 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 18, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power Of Attorney